BiotechTube
R3 Vascular

R3 Vascular

Santa Clara, United States· Est.
r3vascular.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

R3 Vascular is a clinical-stage medical device company pioneering next-generation bioresorbable scaffold (BRS) technology for peripheral artery disease. Its lead product, the MAGNITUDE BRS, features the thinnest strut profile ever tested in this clinical setting, aiming to combine the mechanical support of a metal stent with the long-term benefits of complete resorption. Led by a seasoned executive team with a strong track record in vascular device development and commercialization, the company is positioned to address a significant unmet need in the large and growing PAD market. R3 Vascular is currently in the clinical development phase and is pre-revenue.

CardiovascularPeripheral Arterial Disease

Technology Platform

Proprietary bioresorbable polymer and manufacturing process to create ultra-thin (98-micron strut) scaffolds coated with sirolimus for the treatment of peripheral arterial disease.

Funding History

1
Total raised:$20M
Series A$20M

Opportunities

The large and growing global PAD market presents a multi-billion dollar opportunity for a differentiated device.
A successful bioresorbable scaffold could capture significant share from permanent metal stents by offering a superior long-term clinical solution, potentially reducing re-interventions and restoring natural vessel function.
The company's ultra-thin strut technology addresses key historical failure modes of earlier BRS devices.

Risk Factors

The company faces high clinical and regulatory risk, as the BRS must prove safety and efficacy in demanding peripheral anatomy.
It competes against deep-pocketed, established medtech giants with dominant market positions.
As a pre-revenue private company, it is dependent on raising capital to fund expensive clinical trials and operations.

Competitive Landscape

R3 Vascular competes in the peripheral stent market against major players like Abbott, Boston Scientific, and Medtronic, who offer permanent drug-eluting nitinol stents. It also competes with other companies developing bioresorbable technologies for peripheral use. The key differentiator is its claim of the thinnest strut profile, aiming to improve deliverability and healing compared to both metal stents and thicker-strut BRS competitors.

More companies in Drug Delivery & Formulation →More companies in United States →